Shots:

• Spring Bank has discontinued the development of Inarigivir soproxil due to the occurrence of one patient death in its P-IIb CATALYST study
• The discontinuation allows Spring Bank to focus on immuno-oncology & inflammation including its SB 11285 IV STING agonist clinical program in oncology- STING antagonist for inflammatory diseases- and its STING agonist ADC program
• SB 11285 is a STING agonist- currently being evaluated in P-Ia/Ib study with the expected initiation of IND enabling activities for its orally available STING antagonist and advancement in STING agonist ADCs’ pipeline

Click here ­to­ read full press release/ article | Ref: Spring Bank  | Image:  Spring Bank